Melanoma burden by melanoma stage: Assessment through a disease transition model

European Journal of Cancer

Volumn 53, Issue , 2016, Pages 33-41

  Tromme, Isabelle ^a   Legrand, Catherine ^b   Devleesschauwer, Brecht ^b,c   Leiter, Ulrike ^d   Suciu, Stefan ^e   Eggermont, Alexander ^f   Francart, Julie ^g   Calay, Frederic ^g   Haagsma, Juanita A ^h   Baurain, Jean François ^a   Thomas, Luc ⁱ   Beutels, Philippe ^j   Speybroeck, Niko ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e EORTC DATA CENTER   (Belgium)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g Belgian Cancer Registry   (Belgium)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITÉ LYON 1   (France)

^j UNIVERSITY OF ANTWERP   (Belgium)

more..

Author keywords

Disability adjusted life year; Melanoma

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MODEL; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CAUSE OF DEATH; DISABILITY ADJUSTED LIFE YEAR; DISTANT METASTASIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; MORBIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; STUDY; UNCERTAINTY; ADULT; BIOLOGICAL MODEL; DISABLED PERSON; MARKOV CHAIN; MORTALITY; ONSET AGE; PATHOLOGY; SKIN TUMOR; STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGE OF ONSET; DISABLED PERSONS; FEMALE; HUMANS; MALE; MARKOV CHAINS; MELANOMA; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; QUALITY OF LIFE; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 84949552669     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.09.016     Document Type: Article

References (32)

1. A.M. Eggermont, A. Spatz, and C. Robert Cutaneous melanoma Lancet 383 9919 2014 816 827
2. J.L. Rees The melanoma epidemic: reality and artefact BMJ 312 7024 1996 137 138
3. N.J. Levell, C.C. Beattie, S. Shuster, and D.C. Greenberg Melanoma epidemic: a midsummer night's dream? Br J Dermatol 161 3 2009 630 634
4. H.G. Welch, S. Woloshin, and L.M. Schwartz Skin biopsy rates and incidence of melanoma: population based ecological study BMJ 331 7515 2005 481
5. J.J. Grob, M.A. Richard, J. Gouvernet, M.F. Avril, M. Delaunay, P. Wolkenstein, and et al. The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study Int J Cancer 102 1 2002 34 38
6. D. Lipsker Growth rate, early detection, and prevention of melanoma: melanoma epidemiology revisited and future challenges Arch Dermatol 142 12 2006 1638 1640
7. L. Brochez, K. Myny, L. Bleyen, G. De Backer, and J.M. Naeyaert The melanoma burden in Belgium; premature morbidity and mortality make melanoma a considerable health problem Melanoma Res 9 6 1999 614 618
8. D.U. Ekwueme, G.P. Guy Jr., C. Li, S.H. Rim, P. Parelkar, and S.C. Chen The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006 J Am Acad Dermatol 65 5 Suppl. 1 2011 S133 S143
9. V. Sigurdardottir, C. Bolund, Y. Brandberg, and M. Sullivan The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique Qual Life Res 2 3 1993 193 203
10. C. Curiel-Lewandrowski, C.C. Kim, S.M. Swetter, S.C. Chen, A.C. Halpern, J.M. Kirkwood, and et al. Survival is not the only valuable end point in melanoma screening J Invest Dermatol 132 5 2012 1332 1337
11. V. Barzey, M.B. Atkins, L.P. Garrison, Y. Asukai, S. Kotapati, and J.R. Penrod Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis J Med Econ 16 2 2013 202 212
12. C.J. Murray, T. Vos, R. Lozano, M. Naghavi, A.D. Flaxman, C. Michaud, and et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 9859 2012 2197 2223
13. I. Soerjomataram, J. Lortet-Tieulent, D.M. Parkin, J. Ferlay, C. Mathers, D. Forman, and et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions The Lancet 380 9856 2012 1840 1850
14. B. Devleesschauwer, C. Maertens de Noordhout, G.S. Smit, L. Duchateau, P. Dorny, C. Stein, and et al. Quantifying burden of disease to support public health policy in Belgium: opportunities and constraints BMC Public Health 14 2014 1196
15. C. Holterhues, L.M. Hollestein, T. Nijsten, E.R. Koomen, W. Nusselder, and E. de Vries Burden of disease due to cutaneous melanoma has increased in the Netherlands since 1991 Br J Dermatol 169 2 2013 389 397
16. N. Fernandez de Larrea-Baz, E. Alvarez-Martin, C. Morant-Ginestar, R. Genova-Maleras, A. Gil, B. Perez-Gomez, and et al. Burden of disease due to cancer in Spain BMC Public Health 9 2009 42
17. N. Jayatilleke, N. Pashayan, and J.W. Powles Burden of disease due to cancer in England and Wales Journal of Public Health 34 2 2011 287 295
18. Belgian Cancer Registry 2014 http://www.kankerregister.org
19. International Agency for Research on Cancer WHO The GLOBOCAN project 2012 http://globocan.iarc.fr/
20. L.H.G.M. Sobin, and Ch Wittekind TNM classification of malignant tumors 7th ed 2009 Wiley-Blackwell Oxford
21. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, D.R. Byrd, and et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 36 2009 6199 6206
22. I. Tromme, B. Devleesschauwer, P. Beutels, P. Richez, A. Leroy, J.F. Baurain, and et al. Health related quality of life in melanoma patients expressed as utilities and disability weights Br J Dermatol 171 6 2014 1443 1450
23. A. Schlesinger-Raab, G. Schubert-Fritschle, R. Hein, W. Stolz, M. Volkenandt, D. Holzel, and et al. Quality of life in localised malignant melanoma Ann Oncol 21 12 2010 2428 2435
24. C. Holterhues, D. Cornish, L.V. van de Poll-Franse, G. Krekels, F. Koedijk, D. Kuijpers, and et al. Impact of melanoma on patients' lives among 562 survivors: a Dutch population-based study Arch Dermatol 147 2 2011 177 185
25. U. Leiter, P.G. Buettner, T.K. Eigentler, E.B. Brocker, C. Voit, H. Gollnick, and et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry J Am Acad Dermatol 66 1 2012 37 45
26. A.M. Eggermont, S. Suciu, A. Testori, M. Santinami, W.H. Kruit, J. Marsden, and et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma J Clin Oncol 30 31 2012 3810 3818
27. M. Maio, J.J. Grob, S. Aamdal, I. Bondarenko, C. Robert, L. Thomas, and et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial J Clin Oncol 33 10 2015 1191 1196
28. Statistics Belgium Tables de mortalité et espérance de vie 2013 http://statbel.fgov.be/fr/statistiques/chiffres/population/deces-mort-esp-vie/tables/
29. C.J.L. Murray, M. Ezzati, A.D. Flaxman, S. Lim, R. Lozano, C. Michaud, and et al. GBD 2010: design, definitions, and metrics The Lancet 380 9859 2012 2063 2066
30. C.J. Murray Quantifying the burden of disease: the technical basis for disability-adjusted life years Bull World Health Organ 72 3 1994 429 445
31. A. Joosse, S. Collette, S. Suciu, T. Nijsten, F. Lejeune, U.R. Kleeberg, and et al. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials J Clin Oncol 30 18 2012 2240 2247
32. A. Joosse, S. Collette, S. Suciu, T. Nijsten, P.M. Patel, U. Keilholz, and et al. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials J Clin Oncol 31 18 2013 2337 2346